Huapont Life Sciences Co., Ltd.

On July 24, the official website of the State Drug Administration (NMPA) released the latest announcement that betamethasone sodium phosphate injection, a generic drug of Chengdu Brilliant Pharmaceutical Co., Ltd. has been officially approved and deemed to have passed the evaluation. This achievement marks another significant achievement for Bett Pharmaceutical in 2023. According to statistics, since the beginning of the year, Bette Pharmaceutical and its subsidiaries have successfully passed the evaluation of the number of drugs reached 26, which fully demonstrates the company's strong research and development capabilities and market competitiveness. Betamethasone sodium phosphate injection, as a glucocorticoid drug widely used in clinic, plays an important role in the treatment of allergic and autoimmune diseases, such as lupus erythematosus, rheumatoid arthritis, asthma and other chronic diseases. According to the data of pharmaceutical Rongyun, the sales of the drug in the national hospital market in 2023 has exceeded 100 million yuan, an increase of nearly 45%, and the market demand continues to maintain a strong trend. In the field of generic drugs, the production approval of betamethasone sodium phosphate injection is also extremely competitive. At present, a total of 8 domestic enterprises have obtained the production approval of the drug, of which 3 enterprises, such as Chongqing Huabang Pharmaceutical, Chengdu Brilliant Pharmaceutical and Suicheng Pharmaceutical, have successfully passed the evaluation. In addition, there are 17 enterprises are actively reporting the listing of the variety, is in the review and approval stage. In recent years, Bett Pharmaceutical has continuously committed to the enrichment and expansion of its product line, and the number of generic drug approvals has continued to hit a new high. In particular, in 2023, the company and its subsidiaries have successfully passed the evaluation of 26 drug varieties, including three important varieties with first imitation significance, such as Furosemide oral solution. These achievements not only highlight the strong strength of Brilliant Pharmaceutical in the field of research and development, but also provide more high-quality and reliable drug choices for the majority of patients. Looking forward to the future, Bette Pharmaceutical will continue to increase investment in research and development, and continue to promote the enrichment and upgrading of product pipelines. The company is committed to providing patients with better quality and more reliable medical products, and contributing its own strength to the cause of human health.

Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors Pipeline prioritization and workforce restructuring sharpens focus on programs targeting the highest unmet needs and with highest probability of success Priced concurrent $160 million equity offering Erasca to host conference call and webcast Friday, May 17, 2024 at 8:30 am ET SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced it has entered into exclusive license agreements for two preclinical RAS programs—a potential best-in-class pan-RAS molecular glue (ERAS-0015) and a potential first-in-class pan-KRAS inhibitor (ERAS-4001)—and provided a pipeline update. ERAS-0015 and ERAS-4001 are highly potent, orally bioavailable molecules with complementary RAS inhibitory mechanisms that have the potential to address unmet needs in nearly 2.7 million patients who are diagnosed annually globally with RAS-mutant (RASm) tumors, of which over 2.2 million patients are diagnosed with KRAS-mutant (KRASm) tumors. As separately announced, Erasca has priced an equity offering of $160 million with a high quality group of new and existing healthcare-focused investors. “We’re thrilled to add ERAS-0015 and ERAS-4001 to our pipeline. Successful in-licensing of this RAS-targeting franchise with such broad potential to address unmet needs in patients helps advance our mission to erase cancer and is consistent with our focus on eradicating RAS/MAPK pathway-driven tumors,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Based on the compelling preclinical data generated to date, we believe both molecules have the potential to demonstrate best-in-class (BIC) profiles within their respective categories of RAS inhibition. Over the long term, we have a unique opportunity to combine these two BIC molecules with distinct and complementary RAS inhibitory mechanisms to ‘clamp’ RAS and shut down MAPK signaling for the benefit of patients with these common RAS mutations.” Dr. Lim continued, “With the in-licensing of these RAS-targeting programs, we have made the difficult but necessary decision to deprioritize or externalize resourcing of our pipeline (ERAS-007, ERAS-801, and ERAS-4). This change has unfortunately impacted certain team members. We believe that further focusing our resources will allow us to advance the programs with the highest probability of success and largest potential for patient impact. This is undoubtedly a challenging time for our highly talented employees, particularly those affected by these changes. On behalf of Erasca, I would like to extend our heartfelt gratitude to all of our employees for their tremendous contributions and dedication to Erasca.” In-Licensed Programs: ERAS-0015 and ERAS-4001 In controlled preclinical studies using another pan-RAS molecular glue currently in clinical development, ERAS-0015 demonstrated 5- to 10-fold greater in vitro and in vivo potency and favorable absorption, distribution, metabolism, and excretion (ADME) properties and pharmacokinetic (PK) properties in multiple animal species. Under the terms of the ERAS-0015 license agreement, in exchange for an exclusive license to develop and commercialize ERAS-0015 in the Erasca territory (worldwide, excluding mainland China, Hong Kong, and Macau), Erasca will pay the licensor, Joyo Pharmatech Co., Ltd. (Joyo), a one-time upfront cash payment of $12.5 million, up to $176.5 million in cash upon the achievement of certain development, regulatory, and commercialization milestones, and a low- to mid-single digit percentage royalty. At Erasca’s election, prior to the dosing of the first patient in a Phase 2 clinical trial by either Erasca or Joyo or the filing of a New Drug Application (NDA) (or foreign equivalent) by either Erasca or Joyo, Erasca can convert its territory to worldwide by making a one-time payment. ERAS-4001 is a potent and selective inhibitor of KRAS that has the potential to provide an improved therapeutic window relative to RAS inhibitors and prevent KRAS wildtype-mediated resistance relative to mutant-selective approaches. Under the terms of the ERAS-4001 license agreement, in exchange for an exclusive worldwide license to develop and commercialize ERAS-4001, Erasca will pay the licensor, Medshine Discovery, Inc. (Medshine), a one-time upfront cash payment of $10.0 million, up to $160.0 million in cash upon the achievement of certain development, regulatory, and commercialization milestones, and a low-single digit percentage royalty. Concurrent Pipeline Prioritization and Workforce RestructuringIn consideration of these in-licensing transactions, Erasca will implement the following pipeline and personnel changes to focus Erasca’s resources on opportunities targeting the highest unmet needs and having the highest probability of success for patients: HERKULES-3: ERAS-007 + EC in EC-naïve patients with BRAFm CRC: Deprioritized as clinical efficacy data (data to be presented at ASCO 2024) do not support continued evaluationTHUNDERBBOLT-1: ERAS-801 in recurrent glioblastoma: Due to the desire to focus internal resources on developing naporafenib and the RAS-targeting franchise, Erasca is exploring further advancement of ERAS-801 via select investigator-sponsored trial(s)ERAS-4 pan-KRAS program: In conjunction with the in-licensing of ERAS-0015 and ERAS-4001, Erasca will discontinue its internal pan-KRAS program; provided that certain of the existing ERAS-4 molecules are included in the Medshine agreement as potential backup compounds for ERAS-4001Workforce restructuring: Erasca will reduce its workforce by approximately 18%, primarily affecting employees working in drug discovery functions and on deprioritized programs. Erasca is deeply committed to easing this transition for its impacted colleagues and will offer comprehensive severance packages and career transition services Key Upcoming MilestonesErasca is providing the following guidance with respect to anticipated key milestones and clinical trial readouts: Naporafenib (pan-RAF inhibitor) SEACRAFT-1: Phase 1b trial for naporafenib plus trametinib in patients with RAS Q61X solid tumors Initial Phase 1b combination signal-seeking efficacy data in relevant tumor types expected in Q4 2024 SEACRAFT-2: Randomized pivotal Phase 3 trial for naporafenib plus trametinib in patients with NRAS-mutant (NRASm) melanoma Phase 3 pivotal trial initiation expected in Q2 2024Phase 3 Stage 1 randomized dose optimization data expected in 2025 ERAS-0015 (pan-RAS molecular glue) AURORAS-1: Phase 1 trial for ERAS-0015 in patients with RASm solid tumors IND filing expected in H1 2025Initial Phase 1 monotherapy data in relevant tumor types expected in 2026 ERAS-4001 (pan-KRAS inhibitor) BOREALIS-1: Phase 1 trial for ERAS-4001 in patients with KRASm solid tumors IND filing expected in Q1 2025Initial Phase 1 monotherapy data in relevant tumor types expected in 2026 Conference Call and Webcast InformationErasca will hold a conference call and webcast Friday, May 17, 2024 at 8:30 am ET. The webcast link for the conference call is https://viavid.webcasts.com/starthere. The dial-in number is 1-877-451-6152 (U.S./Canada) or 1-201-389-0879 (international). The conference ID for all callers is 13746639. The live webcast and replay may be accessed by visiting Erasca’s website at Erasca.com/events. About ErascaAt Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We have assembled one of the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer. Cautionary Note Regarding Forward-Looking Statements Erasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: our expectations regarding the potential therapeutic benefits of our product candidates, including naporafenib, ERAS-0015, ERAS-4001, and ERAS-801; the potential benefits from our current or future arrangements with third parties, including the anticipated benefits of the license agreements with Medshine Discovery Inc. and Joyo Pharmatech Co., Ltd.; the planned advancement of our development pipeline, including the anticipated timing of data readouts for the SEACRAFT-1, SEACRAFT-2, AURORAS-1, and BOREALIS-1 trials, the initiation of the SEACRAFT-2 trial, and the IND filings for the AURORAS-1 and BOREALIS-1 trials; our ability to successfully prioritize our pipeline portfolio to focus on existing programs that we believe have the highest probability of success; and our ability to realize the benefits of the license agreements described in this press release. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: our approach to the discovery and development of product candidates based on our singular focus on shutting down the RAS/MAPK pathway, a novel and unproven approach; our assumptions about ERAS-0015 or ERAS-4001 development potential are based in large part on the preclinical data generated by the licensors and we may observe materially and adversely different results as we conduct our planned studies; we only have one product candidate in clinical development and all of our other development efforts are in the preclinical or development stage; our planned SEACRAFT trials may not support the registration of naporafenib; our assumptions around which programs may have a higher probability of success may not be accurate, and we may expend our limited resources to pursue a particular product candidate and/or indication and fail to capitalize on product candidates or indications with greater development or commercial potential; potential delays in the commencement, enrollment, data readout, and completion of clinical trials and preclinical studies; our dependence on third parties in connection with manufacturing, research, and preclinical and clinical testing; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval, and/or commercialization, or may result in recalls or product liability claims; unfavorable results from preclinical studies or clinical trials; results from preclinical studies or early clinical trials not necessarily being predictive of future results; the inability to realize any benefits from our current licenses, acquisitions, or collaborations, and any future licenses, acquisitions, or collaborations, and our ability to fulfill our obligations under such arrangements; regulatory developments in the United States and foreign countries; later developments with the FDA or EU health authorities may be inconsistent with the feedback received to date regarding our development plans and trial designs; our ability to obtain and maintain intellectual property protection for our product candidates and maintain our rights under intellectual property licenses; our ability to fund our operating plans with our current cash, cash equivalents, and marketable securities; and other risks described in our prior filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2023, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact:Joyce AllaireLifeSci Advisors, LLCjallaire@lifesciadvisors.com Source: Erasca, Inc.

CHICAGO, June 21, 2023 /PRNewswire/ -- The veterinary API industry is poised for significant growth in the near future. As pet ownership continues to rise and people's awareness of animal health and welfare deepens, the demand for veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) is expected to skyrocket. With advancements in technology and research, the industry is likely to witness the development of innovative APIs that are more efficient and tailored to specific animal species, ensuring optimal therapeutic outcomes. Additionally, there is a growing focus on the use of natural and herbal APIs, reflecting the increasing preference for holistic and alternative veterinary treatments. Furthermore, the integration of digital solutions, such as telemedicine and remote monitoring, will revolutionize veterinary care, enabling accurate diagnosis, personalized treatment plans, and enhanced overall healthcare for animals. The veterinary API industry, driven by these transformative trends, is set to make significant strides in improving animal health and well-being in the near future. Veterinary API Market in terms of revenue was estimated to be worth $5.2 billion in 2023 and is poised to reach $7.1 billion by 2028, growing at a CAGR of 6.5% from 2023 to 2028 according to a new report by MarketsandMarkets™. The market for veterinary API is expanding because of factors like rising incidence of transboundary & zoonotic diseases, increasing animal population and pet ownership, and increasing disease control & disease prevention measures. The veterinary API industry is anticipated to develop because of the rising demand for veterinary medicines and other animal health products. This is also going to attract international investors to that region. Download an Illustrative overview: Browse in-depth TOC on "Veterinary API Market" 150 - Tables 60 - Figures 350 - Pages Veterinary API Market Scope: In this report, the Veterinary API Market is segmented based on API Type, Synthesis Type, Route of Administration, Animal Type, and region. "Oral segment in Route of administration was dominated by the highest share in Veterinary API Market" The Veterinary API Market is divided into four types based on Route of administration such as Oral, Injectable, Topical, and Others. The Oral segment accounted for the highest share of the global Veterinary API Market in 2022. Oral administration of veterinary drugs is relatively easy and can be performed by the pet owner or veterinary professional. It typically involves the use of tablets, capsules, liquids, or treats that can be readily consumed by animals. The oral route is suitable for a wide range of veterinary drugs, including antibiotics, antiparasitics, analgesics, and medications for chronic conditions. "Companion animal segment was dominated by the highest share in Veterinary API Market" The Veterinary API Market is segmented based on animal type into two categories: companion animals and livestock animals. In 2022, companion animals dominated the Veterinary API Market, holding the largest market share. This can be attributed to the increasing focus on preventive healthcare for companion animals and the rise in pet ownership, among other factors. These factors have contributed significantly to the significant proportion of the market occupied by companion animals. "North America accounted for the largest share of the Veterinary API Market in 2022" The Veterinary API Market is categorized into five geographical regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America emerged as the dominant region, capturing the largest market share for Veterinary APIs globally. The growth of the North America market is expected to be driven by factors such as increased investments in research and development for veterinary API manufacturing and government backing for the establishment of API manufacturing facilities. Request Sample Pages: Veterinary API Market Dynamics: Drivers: Rising incidence of transboundary & zoonotic diseases Increasing animal population and pet ownership Increasing disease control & disease prevention measures Growing demand for animal protein Restraints: High costs of veterinary diagnostic and treatment Growing concerns about antibiotic resistance Opportunities: Rising awareness about animal health and welfare Untapped emerging economies Challenges: Growing concerns about antibiotic resistance Challenges In Large Molecule Api Synthesis Key Market Players: The prominent players in the global Veterinary API Market are Phibro Animal Health Corporation (US), Fabbrica Italiana Sintetici S.p.A. (Italy), Sequent Scientific Ltd. (India), Excel Industries Ltd. (India), NGL Fine-Chem Ltd. (India), Insulnsud Pharma (Spain), Menadiona Sl (Spain), Rochem International Inc. (US), and Shaanxi Hanjiang Pharmaceutical Group Co. Ltd. (China) Get 10% Free Customization on this Report: Recent Developments: In 2021, Sequent Scientific Ltd. (India) received WHO–GENEVA approval for API Praziquantel (Anthelmintic) under the prequalification program. In 2020, Sequent Scientific Ltd. Opened a state-of-the-art animal health R&D center in Mumbai, India. Veterinary API Market Advantages: Improved Animal Health: Veterinary APIs play a crucial role in developing and manufacturing medications for animals. These APIs serve as the core therapeutic components in veterinary drugs, enabling effective treatment and management of various diseases and health conditions in animals. By providing essential ingredients for veterinary medications, APIs help improve animal health and overall well-being. Diverse Treatment Options: The Veterinary API market offers a wide range of APIs that cater to different animal species and conditions. This diversity allows veterinarians and animal health professionals to choose from various therapeutic options and tailor treatments according to specific needs. The availability of different APIs expands the scope of veterinary medicine, providing versatile solutions for animal healthcare. Research and Development: The Veterinary API market promotes continuous research and development in animal health. Pharmaceutical companies invest in the discovery and development of new APIs to address emerging diseases and improve existing treatments. This focus on research drives innovation in the veterinary sector and fosters the development of more effective and safer drugs for animals. Regulatory Compliance: The Veterinary API market operates within a regulated framework to ensure product safety and quality. APIs used in veterinary medications undergo stringent quality control measures and regulatory compliance to meet the standards set by regulatory authorities. These regulations contribute to the reliability and trustworthiness of veterinary APIs, assuring veterinarians and animal owners of the safety and efficacy of the medications. Global Market Growth: The global demand for veterinary medications is increasing due to factors such as pet ownership growth, rising awareness about animal health, and the expansion of livestock production. This growth in demand drives the Veterinary API market forward, creating opportunities for manufacturers, suppliers, and distributors. As a result, the market experiences steady growth, attracting investments and fostering economic development. Technological Advancements: The Veterinary API market benefits from advancements in pharmaceutical technology, such as improved synthesis methods, drug delivery systems, and formulation techniques. These advancements enhance the bioavailability, stability, and efficacy of veterinary medications, ultimately leading to better treatment outcomes for animals. The integration of technology into the production and development of APIs contributes to the overall advancement of veterinary medicine. Collaboration and Partnerships: The Veterinary API market encourages collaboration and partnerships among pharmaceutical companies, research institutions, and veterinary professionals. These collaborations facilitate knowledge sharing, joint research projects, and the development of innovative solutions for animal health. By fostering collaboration, the Veterinary API market strengthens the collective expertise and resources dedicated to improving veterinary healthcare. Overall, the Veterinary API market plays a vital role in the development and availability of effective veterinary medications. It contributes to the growth of the animal health industry, enhances treatment options, promotes research and innovation, and ensures regulatory compliance, ultimately leading to improved animal health outcomes. Objectives of the Study: To define, describe, segment, and forecast the Veterinary API Market based on API type, Synthesis Type, Route of Administration, Animal Type, and region. To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges). To assess the Veterinary API Market regarding Porter's five forces analysis, regulatory landscape, value chain, supply chain, ecosystem analysis, patent analysis, and the impact of the economic recession. To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market. To forecast the size of the Veterinary API Market in North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. To analyze opportunities in the market for stakeholders and provide details of the competitive landscape. To profile the key players in the Veterinary API Market and comprehensively analyze their core competencies. To track and analyze competitive developments such as product launches and approvals, acquisitions, expansions, partnerships, and agreements in the Veterinary API Market. Related Reports: Veterinary Pain Management Market - Global Forecasts to 2027 Companion Animal Diagnostics Market - Global Forecasts to 2027 Companion Animal Pharmaceuticals Market - Global Forecasts to 2027 Therapeutic Drug Monitoring Market - Global Forecasts to 2027 Animal Antibiotics and Antimicrobials Market - Global Forecasts to 2027 About MarketsandMarkets™: MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit ™.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: [email protected] Research Insight: Visit Our Website: Content Source: Logo: SOURCE MarketsandMarkets